Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. - Attard,G.; Reid,A.H.; Yap,T.A. (J Clin Oncol, 2008)